These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 17358100)
1. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Raslová K; Tamer SC; Clauson P; Karl D Clin Drug Investig; 2007; 27(4):279-85. PubMed ID: 17358100 [TBL] [Abstract][Full Text] [Related]
2. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604 [TBL] [Abstract][Full Text] [Related]
3. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Bartley PC; Bogoev M; Larsen J; Philotheou A Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078 [TBL] [Abstract][Full Text] [Related]
5. Insulin detemir: a review of its use in the management of diabetes mellitus. Keating GM Drugs; 2012 Dec; 72(17):2255-87. PubMed ID: 23110609 [TBL] [Abstract][Full Text] [Related]
6. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Chapman TM; Perry CM Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157 [TBL] [Abstract][Full Text] [Related]
7. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Hermansen K; Davies M Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147 [TBL] [Abstract][Full Text] [Related]
8. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Frier BM; Russell-Jones D; Heise T Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900 [TBL] [Abstract][Full Text] [Related]
9. Defining the role of insulin detemir in Basal insulin therapy. Morales J Drugs; 2007; 67(17):2557-84. PubMed ID: 18034591 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473 [TBL] [Abstract][Full Text] [Related]
11. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. Chapman TM; Perry CM BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219 [TBL] [Abstract][Full Text] [Related]
12. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321 [TBL] [Abstract][Full Text] [Related]
13. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758 [TBL] [Abstract][Full Text] [Related]
14. Insulin detemir: a long-acting insulin product. Jones MC; Patel M Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694 [TBL] [Abstract][Full Text] [Related]
15. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Davies MJ; Derezinski T; Pedersen CB; Clauson P Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200 [TBL] [Abstract][Full Text] [Related]
17. Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. Zachariah S; Sheldon B; Shojaee-Moradie F; Jackson NC; Backhouse K; Johnsen S; Jones RH; Umpleby AM; Russell-Jones DL Diabetes Care; 2011 Jul; 34(7):1487-91. PubMed ID: 21593292 [TBL] [Abstract][Full Text] [Related]
18. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Raslová K; Bogoev M; Raz I; Leth G; Gall MA; Hâncu N Diabetes Res Clin Pract; 2004 Nov; 66(2):193-201. PubMed ID: 15533587 [TBL] [Abstract][Full Text] [Related]
19. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L; Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957 [TBL] [Abstract][Full Text] [Related]
20. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Philis-Tsimikas A; Charpentier G; Clauson P; Ravn GM; Roberts VL; Thorsteinsson B Clin Ther; 2006 Oct; 28(10):1569-81. PubMed ID: 17157113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]